2024 Annual Meeting of the Korean Society of Gene and Cell Therapy
Nov 14 - Nov 15, 2024
Catholic University of Korea - Songeui Campus, Omnibus Park
Booth 19
The 19th Annual Meeting of the Korean Society of Gene and Cell Therapy in Seoul, Korea, is a premier event for professionals in the gene and cell therapy fields. This conference brings together leading researchers, clinicians and industry experts to discuss the latest advancements, challenges and future directions in gene and cell therapy. Attendees can expect a comprehensive program featuring keynote lectures, scientific sessions, poster presentations and networking opportunities
Come talk to MaxCyte and Chayon Laboratories, our Korean distributor, to learn about our cell engineering technologies that can significantly enhance research and clinical outcomes. Our Flow Electroporation technology enables high-efficiency transfection of a wide range of cell types, which is crucial for gene editing, cell therapy and biomanufacturing applications. MaxCyte’s team of experts can provide valuable insights and technical support, helping you overcome challenges in your projects. Our experience in regulatory compliance and clinical development can also guide you through the complex landscape of bringing new therapies to market.
Luncheon symposium
Exploring Innovative Cell Engineering Methods with MaxCyte's Scalable Electroporation
Friday, November 15, 2024, from 12:30-13:00 in the conference room
Genome engineering of primary human cells and iPSCs holds great promise for the treatment of diseases including cancer or genetic disorders. However, viral cell engineering has several limitations, including high cost, lengthy manufacturing processes and the risk associated with viral integration into the host genome. Therefore, a non-viral genome editing approach is gaining traction from basic to clinical research. MaxCyte electroporation efficiently delivers genome editing tools in the form of DNA, mRNA, and RNP into a wide variety of primary cells and stem cells. Here, we discuss considerations when delivering different types of cargo into primary cells, including gamma delta T cells, macrophages, and MSCs. Moreover, we demonstrate high editing efficiency using MaxCyte electroporation to deliver CRISPR-Cas9 gene-editing machinery into human keratinocytes, iPSCs, NK cells and activated T cells for knock-out and knock-in applications while maintaining high cell viability.
Presenter
